Previous 10 | Next 10 |
Image source: The Motley Fool. Mesoblast (NASDAQ: MESO) Q4 2020 Earnings Call Aug 26, 2020 , 6:00 p.m. ET Operator Continue reading
Mesoblast Limited (MESO) Q4 2020 Earnings Conference Call August 26, 2020 6:00 P.M. ET Company Participants Silviu Itescu - Chief Executive Officer and Managing Director Josh Muntner - Chief Financial Officer Fred Grossman - Chief Medical Officer Conference Call Participants ...
The following slide deck was published by Mesoblast Limited in conjunction with their 2020 Q4 earnings Read more ...
Mesoblast (NASDAQ: MESO ) : FY GAAP EPS of -$0.147. More news on: Mesoblast Limited, Earnings news and commentary, Healthcare stocks news, Read more ...
NEW YORK, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today reported operational highlights and financial results for the fourth quarter and full-year ended June 30, 2020 (FY2020). Mesoblast Chief Executive Dr Silviu Itescu stated: “We are very plea...
NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, will host a webcast to discuss its financial and operational highlights for the fourth quarter and full-year ended June 30, 2020 (FY2020). ...
TG Therapeutics reports development for Umbralisib TG Therapeutics Inc. ( TGTX ) reported that the FDA has accepted its New Drug Application for umbralisib. The drug candidate will be reviewed under the Priority Review pathway. It had been granted Breakthrough Therapy tag for treating ma...
Gainers: Midatech Pharma (NASDAQ: MTP ) +59% . More news on: Midatech Pharma plc, Mesoblast Limited, Sky Solar Holdings, Ltd., Stocks on the move, , Read more ...
Shares of Mesoblast (NASDAQ: MESO) were skyrocketing 49.5% higher as of 11:23 a.m. EDT on Friday. The huge jump came after the Australian biotech announced an FDA advisory committee vote recommending approval of Ryoncil in treating pediatric patients with steroid-refractory acute graft versu...
Taiwan Liposome (NASDAQ: TLC ) +103% on planned trial of inhaled malaria drug for COVID-19. More news on: Taiwan Liposome Company, Ltd., Mesoblast Limited, Midatech Pharma plc, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-23 14:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for MESO on July 23, 2024 12:57PM ET. MESO was trading at $8.29 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 5 - Buy, 2 - H...
NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the United States Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) resubmission for...
NEW YORK, July 21, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced today that the confirmatory Phase 3 trial of its allogeneic, immunoselected, and industrially manufactured stromal cell product...